<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(1)</volume><submitter>Karam S</submitter><pubmed_abstract>The highest financial and symptom burdens and the lowest health-related quality-of-life scores are seen in people with kidney failure. A total of 11 countries in the International Society of Nephrology (ISN) Middle East region responded to the ISN-Global Kidney Health Atlas. The prevalence of chronic kidney disease (CKD) in the region ranged from 4.9% in Yemen to 12.2% in Lebanon, whereas prevalence of kidney failure treated with dialysis or transplantation ranged from 152 per million population (pmp) in the United Arab Emirates to 869 pmp in Kuwait. Overall, the incidence of kidney transplantation was highest in Saudi Arabia (20.2 pmp) and was lowest in Oman (2.2 pmp). Chronic hemodialysis (HD) and peritoneal dialysis (PD) services were available in all countries, whereas kidney transplan</pubmed_abstract><journal>Kidney international supplements</journal><pagination>57-70</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11010631</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Capacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).</pubmed_title><pmcid>PMC11010631</pmcid><pubmed_authors>Jindal K</pubmed_authors><pubmed_authors>Tonelli M</pubmed_authors><pubmed_authors>Zaidi D</pubmed_authors><pubmed_authors>Abou-Jaoudeh P</pubmed_authors><pubmed_authors>Cheikh Hassan HI</pubmed_authors><pubmed_authors>Donner JA</pubmed_authors><pubmed_authors>Anwar S</pubmed_authors><pubmed_authors>Davison SN</pubmed_authors><pubmed_authors>Ekrikpo UE</pubmed_authors><pubmed_authors>Malik C</pubmed_authors><pubmed_authors>Johnson DW</pubmed_authors><pubmed_authors>Diongole HM</pubmed_authors><pubmed_authors>Caskey FJ</pubmed_authors><pubmed_authors>Alshamsi IR</pubmed_authors><pubmed_authors>Cho Y</pubmed_authors><pubmed_authors>Saad S</pubmed_authors><pubmed_authors>Bahous SA</pubmed_authors><pubmed_authors>Tiv S</pubmed_authors><pubmed_authors>Damster S</pubmed_authors><pubmed_authors>Al Hussain T</pubmed_authors><pubmed_authors>Sozio SM</pubmed_authors><pubmed_authors>Lalji R</pubmed_authors><pubmed_authors>Savaj S</pubmed_authors><pubmed_authors>Ibrahim KS</pubmed_authors><pubmed_authors>Wainstein M</pubmed_authors><pubmed_authors>Neuen BL</pubmed_authors><pubmed_authors>Ghnaimat M</pubmed_authors><pubmed_authors>Houston G</pubmed_authors><pubmed_authors>Okpechi IG</pubmed_authors><pubmed_authors>Mitwali A</pubmed_authors><pubmed_authors>Arruebo S</pubmed_authors><pubmed_authors>Fung WW</pubmed_authors><pubmed_authors>Wannous H</pubmed_authors><pubmed_authors>Al Salmi ISA</pubmed_authors><pubmed_authors>Yeung EK</pubmed_authors><pubmed_authors>Davids MR</pubmed_authors><pubmed_authors>Kelly DM</pubmed_authors><pubmed_authors>Nangaku M</pubmed_authors><pubmed_authors>Bello AK</pubmed_authors><pubmed_authors>Cai G</pubmed_authors><pubmed_authors>Irish G</pubmed_authors><pubmed_authors>Saeed B</pubmed_authors><pubmed_authors>Ethier I</pubmed_authors><pubmed_authors>Olanrewaju TO</pubmed_authors><pubmed_authors>Ghimire A</pubmed_authors><pubmed_authors>Ossareh S</pubmed_authors><pubmed_authors>See E</pubmed_authors><pubmed_authors>Nalado AM</pubmed_authors><pubmed_authors>Tungsanga S</pubmed_authors><pubmed_authors>Abu-Alfa AK</pubmed_authors><pubmed_authors>Hooman N</pubmed_authors><pubmed_authors>Levin A</pubmed_authors><pubmed_authors>Htay H</pubmed_authors><pubmed_authors>Riaz P</pubmed_authors><pubmed_authors>Alrukhaimi M</pubmed_authors><pubmed_authors>Divyaveer S</pubmed_authors><pubmed_authors>Amouzegar A</pubmed_authors><pubmed_authors>Osman MA</pubmed_authors><pubmed_authors>Viecelli A</pubmed_authors><pubmed_authors>Petrova A</pubmed_authors><pubmed_authors>Alyousef A</pubmed_authors><pubmed_authors>Sakajiki AM</pubmed_authors><pubmed_authors>Karam S</pubmed_authors><pubmed_authors>Regional Board and ISN-GKHA Team Authors</pubmed_authors><pubmed_authors>Al Ghamdi SMG</pubmed_authors><pubmed_authors>Mortazavi M</pubmed_authors><pubmed_authors>Jha V</pubmed_authors><pubmed_authors>Ye F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Capacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).</name><description>The highest financial and symptom burdens and the lowest health-related quality-of-life scores are seen in people with kidney failure. A total of 11 countries in the International Society of Nephrology (ISN) Middle East region responded to the ISN-Global Kidney Health Atlas. The prevalence of chronic kidney disease (CKD) in the region ranged from 4.9% in Yemen to 12.2% in Lebanon, whereas prevalence of kidney failure treated with dialysis or transplantation ranged from 152 per million population (pmp) in the United Arab Emirates to 869 pmp in Kuwait. Overall, the incidence of kidney transplantation was highest in Saudi Arabia (20.2 pmp) and was lowest in Oman (2.2 pmp). Chronic hemodialysis (HD) and peritoneal dialysis (PD) services were available in all countries, whereas kidney transplan</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2025-04-04T09:34:18.895Z</modification><creation>2024-11-12T11:19:13.754Z</creation></dates><accession>S-EPMC11010631</accession><cross_references><pubmed>38618498</pubmed><doi>10.1016/j.kisu.2024.01.009</doi></cross_references></HashMap>